[阿尔茨海默病中疾病调节药物导致的淀粉样蛋白相关成像异常的发病机制和治疗方法]。

Q3 Medicine

Brain and Nerve Pub Date : 2024-09-01 DOI:10.11477/mf.1416202726

Hidekazu Tomimoto

{"title":"[阿尔茨海默病中疾病调节药物导致的淀粉样蛋白相关成像异常的发病机制和治疗方法]。","authors":"Hidekazu Tomimoto","doi":"10.11477/mf.1416202726","DOIUrl":null,"url":null,"abstract":"Amyloid-related imaging abnormalities (ARIA) represent the most frequent adverse effect of lecanemab, a monoclonal antibody drug that targets amyloid beta. ARIA is observed in approximately 20% of patients who receive lecanemab. Most patients are asymptomatic; however, some develop serious neurological symptoms, and optimal management remains clinically challenging in such cases. In this review, I summarize the pathomechanism underlying ARIA and associated disorders, in addition to countermeasures for ARIA.","PeriodicalId":52507,"journal":{"name":"Brain and Nerve","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Pathogenesis and Treatment of Amyloid-related Imaging Abnormalities Caused by Disease-modifying Drugs in Alzheimer's Disease].\",\"authors\":\"Hidekazu Tomimoto\",\"doi\":\"10.11477/mf.1416202726\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Amyloid-related imaging abnormalities (ARIA) represent the most frequent adverse effect of lecanemab, a monoclonal antibody drug that targets amyloid beta. ARIA is observed in approximately 20% of patients who receive lecanemab. Most patients are asymptomatic; however, some develop serious neurological symptoms, and optimal management remains clinically challenging in such cases. In this review, I summarize the pathomechanism underlying ARIA and associated disorders, in addition to countermeasures for ARIA.\",\"PeriodicalId\":52507,\"journal\":{\"name\":\"Brain and Nerve\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Brain and Nerve\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.11477/mf.1416202726\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brain and Nerve","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11477/mf.1416202726","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

淀粉样蛋白相关成像异常（ARIA）是莱卡内单抗（一种针对淀粉样蛋白 beta 的单克隆抗体药物）最常见的不良反应。大约 20% 的患者在接受左卡尼单抗治疗后会出现淀粉样蛋白相关成像异常。大多数患者无症状，但也有一些患者会出现严重的神经系统症状，在这种情况下，优化治疗仍具有临床挑战性。在这篇综述中，我总结了ARIA和相关疾病的病理机制，以及针对ARIA的对策。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

[Pathogenesis and Treatment of Amyloid-related Imaging Abnormalities Caused by Disease-modifying Drugs in Alzheimer's Disease].

Amyloid-related imaging abnormalities (ARIA) represent the most frequent adverse effect of lecanemab, a monoclonal antibody drug that targets amyloid beta. ARIA is observed in approximately 20% of patients who receive lecanemab. Most patients are asymptomatic; however, some develop serious neurological symptoms, and optimal management remains clinically challenging in such cases. In this review, I summarize the pathomechanism underlying ARIA and associated disorders, in addition to countermeasures for ARIA.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Brain and Nerve Medicine-Neurology (clinical)

自引率

0.00%

发文量